EcoDrugPlus

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSMLUG00000025622
Gene Symbol: CHRM4
2 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSMLUG00000008312
Gene Symbol: CHRM5
2 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSMLUG00000005856
Gene Symbol: CHRNA7
2 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSMLUG00000007541
Gene Symbol: CHRNB2
2 Cross references
197 Possible Orthologues:

Chymase 1

Ensembl ID : ENSMLUG00000010310
Gene Symbol: CMA1
2 Cross references
293 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMLUG00000029641
Gene Symbol: F2R
2 Cross references
327 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSMLUG00000017631
Gene Symbol: F2
2 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSMLUG00000016369
Gene Symbol: F3
2 Cross references
243 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSMLUG00000013966
Gene Symbol: F7
2 Cross references
274 Possible Orthologues:

Coagulation Factor Xii

Ensembl ID : ENSMLUG00000009504
Gene Symbol: F12
2 Cross references
185 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSMLUG00000007235
Gene Symbol: CCDC6
2 Cross references
219 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSMLUG00000013226
Gene Symbol: CSF1R
2 Cross references
206 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).